 Home > Active Ingredient News > Antitumor Therapy > Lancet Gastroenterol Hepatol: Is it necessary for patients with advanced esophageal cancer to undergo palliative radiotherapy after esophageal stent placement?

Lancet Gastroenterol Hepatol: Is it necessary for patients with advanced esophageal cancer to undergo palliative radiotherapy after esophageal stent placement?

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

acetone hazard label

1 6 symbol

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The median survival time of patients with advanced esophageal cancer is 3-6 months, and most patients need intervention for dysphagia.

prevention

This is a multicenter, open-label phase 3 randomized controlled trial that recruited incurable esophageal cancer patients 16 years of age and older who received SMS implantation as the primary management measure for dysphagia , and 1:1 randomized stent implantation Later, he received only routine care or additional EBRT (20 Gy, 5 times; or 30 Gy, 10 times).

management

A total of 220 patients were recruited from December 16, 2013 to August 24, 2018, of which 199 were included in the adjusted intention-to-treat (ITT) population: 102 and 97 patients in the routine care group and EBRT group, respectively.

Survival rate without worsening dysphagia and overall survival rate

Radiotherapy did not reduce the deterioration of dysphagia.

Radiotherapy cannot reduce the worsening of dysphagia.

In the cost-utility analysis, EBRT is more expensive than conventional care, but the efficacy is worse.

For patients with advanced esophageal cancer who receive SEMS implantation as the first choice to relieve dysphagia, palliative radiotherapy does not provide additional benefits, so it should not be used routinely.

Original source:

Douglas Adamson, et al.

org/10.
1016/S2468-1253(21)00004-2" target="_blank" rel="noopener">Palliative radiotherapy after oesophageal cancer stenting (ROCS ): a multicentre, open-label, phase 3 randomised controlled trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.